Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 + Tislelizumab or Prior CPI + Docetaxel vs Docetaxel in NSCLC
NCT06745908Phase 3Recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of nogapendekin alfa inbakicept in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by ImmunityBio, Inc. Primary endpoint: Overall Survival at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06745908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745908.